

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: April 28, 2005

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/633,532
Filing Date	8/5/2003
First Named Inventor	David Reginald ADAMS
Group Art Unit	1624
Examiner Name	V. Balasubramanian
Attorney Docket Number	040283-0204

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
VB	B1	6,365,598	B1	Adams et al.	04/02/02	
M	B2	6,380,238	B1	Adams et al.	04/30/02	
M	B3	6,433,175	B1	Adams et al.	08/13/02	
M	B4	6,552,062	B1	Adams et al.	04/22/03	
M	B5	6,706,750	B1	Bentley	03/16/04	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
VB	B6	REDMOND, "Mood Disorders in the Female Patient," <u>Int. J. Fertility and Women's Medicine</u> , (1997) 42(2), p. 67-72	
M	B7	VALENTIN et al., "Differential Involvement of Serotonin 2A/C and Thromboxane A ₂ /Prostanoid Receptors in High- vs. Low-Shear Rate Arterial Thrombosis in Rabbits," <u>The Journal of Pharmacology and Experimental Therapeutics</u> , (1997) 280(2), p. 761-769	
M	B8	UPTON et al., "Studies on the role of 5-HT _{2C} and 5-HT _{2A} receptors in regulating generalized seizure threshold in rodents," <u>European Journal of Pharmacology</u> , (August 1998) 359, p. 33-40	
M	B9	KUBIN et al., "Serotonergic excitatory drive to hypoglossal motoneurons in the decerebrate cat," <u>Neuroscience Letters</u> , (1992) 139, p. 243-248	
M	B10	KENNETT, "5-HT _{1C} receptors and their therapeutic relevance," <u>Curr. Opin. Invest. Drugs</u> , (April 1993) 2(4), p. 317-362	

Examiner Signature

V. Balasubramanian

Date Considered

7/7/05


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

002.1385570.1



Atty. Dkt. No. 040283-0204

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: David Reginald ADAMS et al.

Title: PIRAZINO(AZA) INDOLE
DERIVATIVES

Appl. No.: 10/633,532

Filing Date: 8/5/2003

Examiner: V. Balasubramanian

Art Unit: 1624

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop PATENT APPLICATION
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

04/29/2005 SZEWDIE1 00000131 10633532

02 FC:1806

180.00 0P

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

STATEMENT

The undersigned hereby states in accordance with 37 CFR §1.97(e)(1) that each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to filing of this Statement.

The undersigned hereby states in accordance with 37 CFR §1.704(d) that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR §1.56(c) more than thirty days prior to the filing of the information disclosure statement.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or

even entirely missing, the Commissioner is authorized to charge the unpaid amount to
Deposit Account No. 19-0741.

Respectfully submitted,

Date April 28, 2005

By



FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5300
Facsimile: (202) 672-5399

Matthew E. Mulkeen
Attorney for Applicant,
Registration No. 44,250